Supernus Q3 GAAP net loss $16M; raises FY adjusted op earnings guide to $95-110M

SUPERNUS PHARMACEUTICALS, INC.

2023-Q3 EPS reported $0.00 revenue$443,207,000

Total revenues $153.9M; Qelbree net sales $37.1M (+103% YoY), GOCOVRI $32.9M (+18% YoY).
GAAP net loss of $16.0M ($0.29 diluted EPS); adjusted operating earnings $37.3M, up 47% YoY.
FY 2023 adjusted operating earnings guidance raised to $95-110M from $75-100M; total revenue guidance $590-610M.
FDA accepted SPN-830 NDA resubmission for Parkinson's; PDUFA date April 5, 2024.
Qelbree IQVIA prescriptions 163,344 (+73% YoY); prescriber base expanded to ~24,189.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. updated its the third quarter ended September 30, 2023 guidance (raised).

Period: the third quarter ended September 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On November 8, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2023. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-23-000070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.